Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Nasdaq Real Time Price USD

Silexion Therapeutics Corp (SLXN)

Compare
1.0400
-0.0600
(-5.45%)
At close: 4:00:00 PM EDT
1.0900
+0.05
+(4.81%)
After hours: 4:41:07 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SLXN

Recent News: SLXN

View More
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
GlobeNewswire 4 days ago
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
GlobeNewswire 11 days ago
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire 14 days ago

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
Business Wire 15 days ago
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
GlobeNewswire 27 days ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
Business Wire 29 days ago
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
GlobeNewswire last month
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
GlobeNewswire last month
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
Business Wire 2 months ago
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
GlobeNewswire 2 months ago

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
Business Wire 2 months ago
View More

Related Tickers

DWTX Dogwood Therapeutics, Inc.
4.9200
-1.80%
 
PLRZ Polyrizon Ltd.
0.3646
-1.19%
 
BDRX Biodexa Pharmaceuticals Plc
1.2000
-9.09%
 
RNAZ TransCode Therapeutics, Inc.
0.5409
+9.27%
 
PALI Palisade Bio, Inc.
0.6698
-1.62%
 
CERO CERo Therapeutics Holdings, Inc.
0.7200
-1.37%
 
ENVB Enveric Biosciences, Inc.
1.3100
-5.76%
 
ADTX Aditxt, Inc.
4.5200
+0.78%
 
PHIO Phio Pharmaceuticals Corp.
1.2300
-5.38%
 
TVGN Tevogen Bio Holdings Inc.
1.0900
+0.93%